Study analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors

A New Jer­sey fed­er­al judge is al­low­ing John­son & John­son to bring new chal­lenges to ev­i­dence brought by plain­tiffs in the com­pa­ny’s mul­ti­dis­trict talc lit­i­ga­tion.

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

ICG-124 is under clinical development by iCell Gene Therapeutics and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).